<DOC>
	<DOCNO>NCT00061672</DOCNO>
	<brief_summary>The primary objective study assess safety effectiveness ABT-510 subject refractory lymphoma .</brief_summary>
	<brief_title>Study Evaluating Safety Effectiveness ABT-510 Subjects With Refractory Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>A subject eligible study participation follow criterion meet : The subject least 18 year age . The subject histologically confirm nonHodgkin 's Lymphoma ( NHL ) ( exclude Burkitt 's , Burkitt 's type HIV associate lymphoma ) Hodgkin 's Lymphoma ( HL ) refractory relapse standard therapy know effective treatment . The subject must measurable disease CHESON Criteria Tumor Response . The subject Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 . The subject able selfadminister caregiver reliably administer subcutaneous injection . The subject must adequate bone marrow , renal hepatic function follow : Bone marrow : *White blood cell count ( WBC ) great equal 3,000/mm3 ; *Platelets great equal 75,000/mm3 unless subject receive prior transplant bone marrow involvement lymphoma document , platelet equal great 50,000 acceptable . *Hemoglobin great equal 8.5 g/dL ; *ANC great equal 1000/mm3 Renal function : *Serum creatinine less equal 2.0 mg/dL Hepatic function : *AST ALT le equal 3.0 X ULN The subject must pregnant lactating subject ( male female ) must use contraceptive method deem appropriate investigator study two month follow completion therapy . The subject voluntarily sign date Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve consent prior study specific procedure . A subject ineligible study participation follow criterion meet : The subject history currently exhibit Central Nervous System ( CNS ) metastasis . Brain MRI within 28 day enrollment require confirm absence CNS metastases . The subject receive therapeutic anticoagulation therapy . Low dose anticoagulation ( e.g. , low dose Coumadin ) catheter prophylaxis permit ; PT/PTT must within normal limit . The subject history currently exhibit clinically significant cancer relate event bleed ( e.g. , hemoptysis ) . The subject recent history ( within 4 week Study Day 1 ) currently exhibit clinically significant event bleed . The subject receive therapy lymphoma include chemotherapy , antibody therapy , radiotherapy investigational therapy within four week prior study drug administration . The subject initiate steroids increase current steroid dose within three month prior study drug administration . The subject exhibit evidence clinically significant uncontrolled condition ( ) and/or consider investigator unable tolerate propose treatment procedure . The subject history previous malignancy within 5 year , exception : Adequately treat situ carcinoma cervix ; Basal squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma ( NHL )</keyword>
	<keyword>Hodgkin 's Lymphoma ( HL )</keyword>
</DOC>